Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 4/20 | 0.47 |
| ▸ | CHRNG | P07510 | 4/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.47 |
| ▸ | CHRND | Q07001 | 4/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 4/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5489864 | 0.99 | CHRNA1 (0.48) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL5492268 | 0.85 | TACR2 (0.57) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL14598259 | 0.84 | CHRNA1 (0.50) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL5494080 | 0.83 | TACR2 (0.55) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL5496976 | 0.83 | TACR2 (0.54) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL14598272 | 0.80 | CHRNB2 (0.52) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL5491193 | 0.80 | TACR2 (0.55) | TACR2ALDH1A1MMP1 | |
| SCHEMBL5496714 | 0.80 | CHRNB2 (0.59) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL5491147 | 0.80 | CHRNB2 (0.59) | CHRNA1CHRNGCHRNB1CHRNDCHRNB2 | |
| SCHEMBL5492106 | 0.80 | GAA (0.46) | CHRNA1CHRNGCHRNB1CHRNDTACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753782-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| WO-2005123770-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | CHRNA1 2663/4885CHRNG 2547/4885CHRNB1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.